KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

NCT05723432 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: KD6001
DRUG: Toripalimab

Sponsor

Shanghai Kanda Biotechnology Co., Ltd.